Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 1:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Double Placebo Clear all
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

NCT07174310
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Prasinezumab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years to 85 Years
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
53
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fullerton, California + 47 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 24, 2026, 1:48 PM EDT
Completed Phase 2 Interventional Results available

Atacicept in Anti-Tumor Necrosis Factor Alpha-naïve Subjects With Rheumatoid Arthritis (AUGUST II)

NCT00595413
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Placebo matched to atacicept, Atacicept: with loading dose, Atacicept, Adalimumab
Drug · Biological
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years and older
Enrollment
311 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Rockland, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 16, 2016 · Synced Sep 24, 2026, 1:48 PM EDT
Terminated Phase 3 Interventional

EN3285 for the Prevention or Delay of Oral Mucositis in Patients With Head and Neck Cancer

NCT00574860
View directory record Official record
Conditions
Oral Mucositis, Head and Neck Cancer
Interventions
EN3285, Placebo, Standard of care
Drug · Other
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
Louisville, Kentucky • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 19, 2013 · Synced Sep 24, 2026, 1:48 PM EDT
Completed Phase 2 Interventional

Norketotifen for the Treatment of Uncomplicated Influenza-like Illness

NCT04043923
View directory record Official record
Conditions
Influenza -Like Illness
Interventions
Norketotifen, Placebo
Drug
Lead sponsor
Emergo Therapeutics, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
18
States / cities
Birmingham, Alabama • Phoenix, Arizona • Long Beach, California + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2021 · Synced Sep 24, 2026, 1:48 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Study to Evaluate the Safety and Efficacy of Intravenously Administered Benralizumab (MEDI-563).

NCT00768079
View directory record Official record
Conditions
Asthma
Interventions
Placebo, Benralizumab
Other · Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
9
States / cities
Tampa, Florida • Springfield, Massachusetts • Detroit, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2020 · Synced Sep 24, 2026, 1:48 PM EDT
Not yet recruiting Phase 2Phase 3 Interventional

A Randomized, Double-Blind Controlled Comparison of NRX-101 vs. Placebo for Adults Being Treated With Robotic Transcranial Magnetic Stimulation for Treatment Resistant Depression: The SPARC-TMS Trial

NCT07227103
View directory record Official record
Conditions
Treatment Resistant Depression, Treatment Resistant Depression (TRD)
Interventions
Neuronavigated robotic-enabled TMS, NRX-101, Sham TMS, Oral Placebo
Device · Drug
Lead sponsor
NeuroRx, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
3
States / cities
Sarasota, Florida • West Palm Beach, Florida • Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Sep 24, 2026, 1:48 PM EDT
Completed Phase 2Phase 3 Interventional Results available

HEALEY ALS Platform Trial - Regimen G DNL343

NCT05842941
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
DNL343, Matching Placebo
Drug
Lead sponsor
Merit E. Cudkowicz, MD
Other
Eligibility
18 Years to 100 Years
Enrollment
249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Sep 24, 2026, 1:48 PM EDT
Completed Phase 3 Interventional

FACTS II: A Study to Test the Safety and Effectiveness of a New Medication on the Treatment of Active Ulcerative Colitis

NCT00064454
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
OPC-6535 Tablets (drug)
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
28
States / cities
Phoenix, Arizona • Tucson, Arizona • Fresno, California + 25 more
Source: ClinicalTrials.gov public record
Updated May 9, 2012 · Synced Sep 24, 2026, 1:48 PM EDT
Completed Phase 2 Interventional Results available

Study of GSK1278863 to Reduce Ischemic Events in Patients Undergoing Thoracic Aortic Aneurysm Repair

NCT01920594
View directory record Official record
Conditions
Surgical Procedures
Interventions
GSK1278863, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
13
States / cities
Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2017 · Synced Sep 24, 2026, 1:48 PM EDT
Completed Phase 2 Interventional

Efficacy and Safety of TAK-875 in Combination With Sitagliptin in Participants With Type 2 Diabetes Mellitus

NCT01414920
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo, TAK-875, Sitagliptin, TAK-875 and Sitagliptin
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 80 Years
Enrollment
368 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
80
States / cities
Birmingham, Alabama • Brimingham, Alabama • Chandler, Arizona + 77 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2016 · Synced Sep 24, 2026, 1:48 PM EDT
Completed Phase 2 Interventional

Double Blind Trial in Children With Autism Spectrum Disorder

NCT06058962
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Suramin Sodium
Drug
Lead sponsor
Paxmedica
Industry
Eligibility
4 Years to 17 Years · Male only
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Tarrytown, New York
Source: ClinicalTrials.gov public record
Updated Nov 12, 2023 · Synced Sep 24, 2026, 1:48 PM EDT
Completed Phase 2 Interventional Results available

A Trial of Lipitor (Atorvastatin) for the Treatment of Polycystic Ovary Syndrome (PCOS) in Women With Elevated Low-density Lipoprotein (LDL) Cholesterol

NCT00529542
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
Lipitor, Placebo
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 24, 2014 · Synced Sep 24, 2026, 1:48 PM EDT
Completed Phase 3 Interventional Results available

Peri-Operative Lidocane, Ketamine, or Lidocane and Ketamine Combination, Infusion for Patients Undergoing Spine Surgery

NCT01983020
View directory record Official record
Conditions
Postoperative Pain
Interventions
Lidocaine, Ketamine, Saline
Drug · Other
Lead sponsor
Beth Israel Medical Center
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 14, 2017 · Synced Sep 24, 2026, 1:48 PM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Efficacy and Safety of Abatacept in Adults With Active Primary Sjögrens Syndrome

NCT02915159
View directory record Official record
Conditions
Sjogrens Disease
Interventions
Abatacept, Placebo
Biological · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
19
States / cities
Fullerton, California • Riverside, California • Lakewood, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2020 · Synced Sep 24, 2026, 1:48 PM EDT
Completed Phase 3 Interventional Results available

A Randomized, Double-blind, Placebo Controlled Study to Assess Efficacy, Safety and Tolerability of LCQ908 in Subjects With Familial Chylomicronemia Syndrome

NCT01514461
View directory record Official record
Conditions
Familial Chylomicronemia Syndrome (FCS)
Interventions
LCQ908, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Seatlle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 2, 2015 · Synced Sep 24, 2026, 1:48 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Treatment of Asian Flushing Syndrome With Topical Alpha Agonists

NCT03497442
View directory record Official record
Conditions
Flushing, Alcohol-Related Disorders, Aldehyde Dehydrogenase Deficiency
Interventions
Brimonidine Tartrate, Placebo Vehicle Gel
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
21 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 3, 2020 · Synced Sep 24, 2026, 1:48 PM EDT
Completed Phase 2 Interventional

Phase 2 Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)

NCT00658086
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
ALN-RSV01, normal saline
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
10
States / cities
San Diego, California • San Francisco, California • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2018 · Synced Sep 24, 2026, 1:48 PM EDT
Recruiting Phase 2Phase 3 Interventional

A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease

NCT07363694
View directory record Official record
Conditions
Moderate to Severe Chronic Obstructive Pulmonary Disease
Interventions
PF-07275315 dose 1, PF-07275315-dose 2, Placebo, PF-07275315-dose 3
Drug
Lead sponsor
Pfizer
Industry
Eligibility
35 Years to 80 Years
Enrollment
1,156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
61
States / cities
Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 48 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 24, 2026, 1:48 PM EDT
Completed Phase 2Phase 3 Interventional

AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext

NCT01741194
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
AC-1204, Placebo
Drug
Lead sponsor
Cerecin
Industry
Eligibility
66 Years to 90 Years
Enrollment
418 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
82
States / cities
Birmingham, Alabama • Phoenix, Arizona • Hot Springs, Arkansas + 69 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2021 · Synced Sep 24, 2026, 1:48 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of SP-103 in Subjects With Moderate to Severe Acute Lower Back Pain

NCT05096494
View directory record Official record
Conditions
Moderate to Severe Acute Lower Back Pain
Interventions
SP-103, Placebo
Drug
Lead sponsor
Scilex Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
10
States / cities
Phoenix, Arizona • Fernandina Beach, Florida • Jacksonville, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 24, 2026, 1:48 PM EDT
Completed Phase 3 Interventional Results available

Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine

NCT02605174
View directory record Official record
Conditions
Migraine With or Without Aura
Interventions
Lasmiditan 50 mg, Lasmiditan 100 mg, Lasmiditan 200 mg, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
3,005 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
95
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 80 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2019 · Synced Sep 24, 2026, 1:48 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Micronutrient Supplement for Nurse Burnout

NCT05363410
View directory record Official record
Conditions
Burnout, Professional, Stress, Psychological
Interventions
MagnéVie B6®, Placebo
Dietary Supplement · Other
Lead sponsor
Nutraceuticals Research Institute
Other
Eligibility
20 Years to 59 Years · Female only
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Franklin, Tennessee
Source: ClinicalTrials.gov public record
Updated May 4, 2022 · Synced Sep 24, 2026, 1:48 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

IV Acetaminophen for Postoperative Pain Analgesia After Laparoscopic Hysterectomy

NCT02400580
View directory record Official record
Conditions
Pain
Interventions
IV acetaminophen, placebo
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
183 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 12, 2018 · Synced Sep 24, 2026, 1:48 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Acute D2 Receptor Blockade Induced Neuronal Network Changes in Human Volunteers

NCT01931059
View directory record Official record
Conditions
Imaging of the Brain and Antipsychotics, Neuronal Network Changes
Interventions
Risperidone, Placebo
Drug · Other
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 60 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Apr 29, 2018 · Synced Sep 24, 2026, 1:48 PM EDT